JAK Inhibitors Prior to Allogeneic Stem Cell Transplant for Patients with Myelofibrosis: A Prospective Study

被引：0
|
作者：
Salit, Rachel B. [1 ]
Stevens, Emily [2 ]
Baker, Kelsey [1 ]
Scott, Bart L. [3 ]
Gooley, Ted Alan [1 ]
Deeg, H. Joachim [4 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Fred Hutchinson Canc Res Ctr, Transplantat Biol, 1124 Columbia St, Seattle, WA 98104 USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Program, 1124 Columbia St, Seattle, WA 98104 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] JAK-2 inhibitors and allogeneic transplant in myelofibrosis
    Patriarca, Francesca
    Sperotto, Alessandra
    De Marchi, Roberta
    Perali, Giulia
    Cigana, Chiara
    Lazzarotto, Davide
    Fanin, Renato
    DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2015, 3 (04): : 237 - 246
  • [2] The effect of pre-transplant JAK 1/2 inhibitors on outcomes of myelofibrosis patients who receive allogeneic stem cell transplant.
    Miller, Kathleen
    Hobbs, Gabriela
    Ho, Vincent T.
    Li, Shuli
    Chen, Yi-Bin Albert
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
    Tiribelli, Mario
    Palandri, Francesca
    Sant'Antonio, Emanuela
    Breccia, Massimo
    Bonifacio, Massimiliano
    BONE MARROW TRANSPLANTATION, 2020, 55 (04) : 708 - 716
  • [4] The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
    Mario Tiribelli
    Francesca Palandri
    Emanuela Sant’Antonio
    Massimo Breccia
    Massimiliano Bonifacio
    Bone Marrow Transplantation, 2020, 55 : 708 - 716
  • [5] REDUCING SPLEEN SIZE BY JAK INHIBITION PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS
    Kroeger, N.
    Alchalby, H.
    Ditschkowski, M.
    Wolf, D.
    Wulf, G.
    Zabelina, T.
    Wolschke, C.
    Stuebig, T.
    Ayuk, F.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S145 - S145
  • [6] Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era
    Maze, Dawn
    Arcasoy, Murat O.
    Henrie, Ryan
    Cerquozzi, Sonia
    Kamble, Rammurti
    Al Hadidi, Samer
    Yacoub, Abdulraheem
    Elsawy, Mahmoud
    Sirhan, Shireen
    Singh, Anurag K.
    Smith, Elliot
    Marcoux, Curtis
    Werner, Dietrich
    Greer, Wenda
    Viswabandya, Auro
    Daly, Andrew
    Sibai, Hassan
    McNamara, Caroline J.
    Xu, Wei
    Lajkosz, Katherine
    Foltz, Lynda
    Gupta, Vikas
    BLOOD, 2020, 136
  • [7] Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
    Gupta, Vikas
    Hari, Parameswaran
    Hoffman, Ronald
    BLOOD, 2012, 120 (07) : 1367 - 1379
  • [8] Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study
    Pu, Jeffrey J.
    Poulose, Joyson
    Malysz, Jozef
    Zhu, Junjia
    Fanburg-Smith, Julie C.
    Claxton, David F.
    Bayerl, Michael G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E130 - E133
  • [9] Allogeneic Stem Cell Transplant in Myelofibrosis Patients: A Real-World Analysis
    Tharakan, Serena
    Sastow, Dahniel
    van Hyfte, Grace
    Mascarenhas, John
    Keyzner, Alla
    Tremblay, Douglas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S433 - S433
  • [10] Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
    Sora, Federica
    Giammarco, Sabrina
    Raiola, Anna Maria
    Di Grazia, Carmen
    Bregante, Stefania
    Gualandi, Francesca
    Varaldo, Riccardo
    Chiusolo, Patrizia
    Sica, Simona
    Laurenti, Luca
    Innocenti, Idanna
    Autore, Francesco
    Metafuni, Elisabetta
    Galli, Eugenio
    Bacigalupo, Andrea
    Angelucci, Emanuele
    BLOOD CANCER JOURNAL, 2022, 12 (07)
12345